Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
20 Results for "
Fc effector function
" in MedChemExpress (MCE) Product Catalog:
Products (20)
20 Results for "Fc effector function" in MCE Product Catalog:
1
1 Cited Publications
Art. -Nr.: HY-P99033
CAS. Nr.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions .
1
Target:
Forschungsgebiete:
1
Target:
Forschungsgebiete:
1
1 Cited Publications
Art. -Nr.: HY-P99300
CAS. Nr.: 1322627-61-1
Synonyms: QGE 031; Anti-IGHE Recombinant Antibody
Target:
Forschungsgebiete:
Art. -Nr.: HY-P990688
CAS. Nr.: 2559056-68-5
Synonyms: AMG-509
Art. -Nr.: HY-P99947
CAS. Nr.: 2540797-21-3
Synonyms: XVR011
Art. -Nr.: HY-P99701
CAS. Nr.: 1450981-87-9
Synonyms: BMS-986004
Target:
Forschungsgebiete:
Art. -Nr.: HY-P990742
CAS. Nr.: 2762499-30-7
Synonyms: TJ-CD4B; ABL111; TJ033721
Target:
Forschungsgebiete:
Givastomig (ABL111, TJ033721) is a bispecific antibody (BsAb) inhibitor. Givastomig can specifically binds to Claudin18.2 (CLDN 18.2) on the surface of cancer cells and 4-1BB (CD137, TNFRSF9) on the surface of activated T cells and natural killer (NK) cells. Givastomig is engineered to contain a single Fc-domain mutation (asparagine to alanine) to eliminate Fc-effector function. Givastomig-bound cell lines expressing a range of CLDN18.2 levels with high affinity and induced 4-1BB activation only in the context of CLDN18.2 binding. Givastomig can be used for the study of colon carcinoma .
Art. -Nr.: HY-177578
Forschungsgebiete:
NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
Art. -Nr.: HY-P991610
Synonyms: Sym025
Forschungsgebiete:
Art. -Nr.: HY-P991582
Target:
Forschungsgebiete:
Art. -Nr.: HY-P992474
Target:
Forschungsgebiete:
TAVO101 is a humanized anti-TSLP antibody with an EC50 of 0.19 nM against hTSLP. TAVO101 inhibits STAT5 activation and CCL17 release. TAVO101 carries Fc region mutations that enhance its binding to FcRn while reducing its binding to FcγRI, FcγRIIIA and C1q, thereby attenuating effector functions. TAVO101 reduces the levels of inflammatory markers, cell infiltration and histopathological damage in preclinical models of asthma, psoriasis and atopic dermatitis. TAVO101 can be used for research related to asthma, psoriasis and atopic dermatitis .
Art. -Nr.: HY-P992163
Forschungsgebiete:
Art. -Nr.: HY-P99670A
Synonyms: CFZ-533 (N297A); OM11-62MF (N297A)
Target:
Forschungsgebiete:
Iscalimab (CFZ-533) (N297A) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). The Fc region of Iscalimab (N297A) incorporates the N297A mutation, designed to remove the N-glycosylation site in the CH2 domain and thereby attenuate or eliminate the antibody's ADCC effector function. Iscalimab (N297A) can be used for research of Graves' hyperthyroidism and autoimmune diseases .
Art. -Nr.: HY-P990876A
Synonyms: PF-06480605 (LALA-GA); RVT-3101 (LALA-GA)
Target:
Forschungsgebiete:
Afimkibart (PF-06480605; RVT-3101) (LALA-GA) is a humanized monoclonal antibody targeting TL1A (TNFSF15). Afimkibart (LALA-GA) blocks the TL1A‑DR3 signaling axis by neutralizing the TL1A ligand, inhibits the release of pro-inflammatory cytokines, suppresses NF-κB activation and IFN-γ production, and simultaneously attenuates fibroblast activation and fibrosis progression associated with this pathway. The Fc region of Afimkibart (LALA-GA) contains the mutations L234A, L235A, and G237A, which are designed to reduce the binding of the antibody to FcγR and C1q, thereby attenuating or eliminating the antibody’s ADCC and CDC effector functions. Afimkibart (LALA-GA) is applicable to research on immune inflammation-related conditions, such as ulcerative colitis .
Art. -Nr.: HY-P99396A
Synonyms: MAB92 (LALA); BI 655130 (LALA)
Target:
Forschungsgebiete:
Spesolimab (MAB92; BI 655130) (LALA) is a humanized IgG1k antibody against IL-36R with a Kd value of 20 pM. Spesolimab (LALA) selectively blocks IL-36R signaling without inhibiting related interleukin pathways. Spesolimab (LALA) lacks functional cross-reactivity with non-human IL-36R and exhibits species-specific binding to human IL-36R, with reduced affinity for mouse, rat, hamster, minipig, and non-human primate IL-36R. Spesolimab (LALA) has L234A and L235A mutations introduced into the Fc region, designed to reduce antibody binding to FcγR and C1q, thereby attenuating/eliminating the ADCC and CDC effector functions of the antibody. Spesolimab (LALA) can be used for research on generalized pustular psoriasis (GPP) .
Art. -Nr.: HY-P992034
Synonyms: PR001
Target:
Forschungsgebiete:
APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis .
Art. -Nr.: HY-P99462A
Synonyms: CDX-0159 (LALQ-KQ, YTE)
Target:
Forschungsgebiete:
Barzolvolimab (CDX-0159) (LALQ-KQ, YTE) is a humanized anti-KIT IgG1 monoclonal antibody. It incorporates the L234A/L235Q/K322Q mutations to silence Fc effector functions, while also featuring the M252Y/S254T/T256E mutations to extend its half-life. Barzolvolimab (LALQ-KQ, YTE) can reduce cutaneous mast cell counts and disease activity in chronic inducible urticaria.
Art. -Nr.: HY-P99355A
Synonyms: Anti-ACVR2B Reference Antibody (LALA); BYM338 (LALA)
Target:
Forschungsgebiete:
Bimagrumab (LALA) (Anti-ACVR2B Reference Antibody (LALA); BYM338 (LALA)) is a monoclonal antibody targeting activin type II receptors (ActRII). Bimagrumab (LALA) binds to human ActRIIB (Kd 1.7 pM) and ActRIIA (Kd 434 pM), blocks ligand binding and downstream Smad activation, and inhibits myostatin/activin A-induced Smad phosphorylation. The Fc region of Bimagrumab (LALA) incorporates L234A and L235A mutations, which are designed to reduce the antibody's binding to FcγR and C1q, thereby attenuating or eliminating its ADCC (antibody-dependent cell-mediated cytotoxicity) and CDC (complement-dependent cytotoxicity) effector functions. Bimagrumab (LALA) induces skeletal muscle hypertrophy in an Akt-independent manner via mTOR-mediated muscle protein synthesis, increases muscle mass and strength, promotes myoblast differentiation/fusion, prevents myotube atrophy and glucocorticoid-induced muscle loss, reduces fat mass and fat depot weight/adipocyte size, inhibits adipose inflammation, induces fat oxidation, preserves lean body mass during incretin-induced weight loss, and enhances the appetite-suppressive effect of incretins. Bimagrumab (LALA) can be used in research on obesity and skeletal muscle atrophy and weakness .
Art. -Nr.: HY-P992546
Target:
Forschungsgebiete:
IBI323 is a PD-L1/LAG-3 dual inhibitory antibody with Kd values of 0.0132 nM and 0.671 nM, respectively. IBI323 blocks the interaction of PD-L1 with PD-1 and CD80, as well as the interaction of LAG-3 with MHC-II. IBI323 mediates cross-linking of PD-L1-positive and LAG-3-positive cells, enhances T cell activation and cytokine secretion, and increases tumor-specific T cells in tumors and blood. IBI323 has a LALA mutation that reduces Fc-mediated effector function and inhibits tumor growth in humanized mouse models. IBI323 can be used for research on melanoma and colon cancer .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
